Publication
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (9)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 9
- cancerLung Adenocarcinomacbioportal_study1.00
- cancerLung Adenocarcinomacivic_curation1.00
- cancerLung Non-Small Cell Carcinomacbioportal_study1.00
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugPembrolizumabcivic_curation1.00
- genePOLD1civic_curation1.00
- variantHighcivic_curation1.00
- variantPOLD1 C284Ycivic_curation1.00
- variantPOLD1 E374Kcivic_curation1.00
Curated evidence
Evidence citing this paper (8)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25765070
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PAPPA2 Y1520X1 | ||||||||
| Pembrolizumab | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4774In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with PAPPA2 Y1520* nonsense mutation, treated with pembrolizumab monotherapy, was associated with a 4 … (full text at CIViC) PMID 25765070 · Rizvi et al., 2015 · Open in CIViC | civic |
| POLD1 C284Y1 | ||||||||
| Pembrolizumab | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID4776In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious (as determined by Polyphen or SIFT) C284Y mutation and a high nonsynonymous mut… (full text at CIViC) PMID 25765070 · Rizvi et al., 2015 · Open in CIViC | civic |
| POLD1 Y956N1 | ||||||||
| Pembrolizumab | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4771In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious Y956N mutation (as determined by Polyphen or SIFT), treated with pembrolizumab … (full text at CIViC) PMID 25765070 · Rizvi et al., 2015 · Open in CIViC | civic |
| POLE4 A59E1 | ||||||||
| Pembrolizumab | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4775In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLE4 deleterious A59E mutation (as determined by Polyphen or SIFT), treated with pembrolizumab m… (full text at CIViC) PMID 25765070 · Rizvi et al., 2015 · Open in CIViC | civic |
| PXDNL P1460T1 | ||||||||
| Pembrolizumab | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4773In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with PXDNL deleterious P1460T mutation, treated with pembrolizumab monotherapy, was associated with a … (full text at CIViC) PMID 25765070 · Rizvi et al., 2015 · Open in CIViC | civic |
| SCN8A Q225X1 | ||||||||
| Pembrolizumab | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | — | submitted | EID4772In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with SCN8A deleterious Q427* mutation, treated with pembrolizumab monotherapy, was associated with a d… (full text at CIViC) PMID 25765070 · Rizvi et al., 2015 · Open in CIViC | civic |
| POLD1 E374K1 | ||||||||
| Pembrolizumab | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID4777In a retrospective study of 34 non-small cell lung cancer patients, a patient, who never smoked, with POLD1 deleterious E374K mutation (as determined by Polyphen or SIFT) and a high nonsynonymous muta… (full text at CIViC) PMID 25765070 · Rizvi et al., 2015 · Open in CIViC | civic |
| High1 | ||||||||
| Pembrolizumab | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12083Exomes were sequenced from two cohorts of non small cell lung cancer patients who were treated with pembrolizumab. In a discovery cohort of 16 patients, durable clinical benefit (DCB - partial or stab… (full text at CIViC) PMID 25765070 · Rizvi et al., 2015 · Open in CIViC | civic |